BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pereira RL, Nascimento IC, Santos AP, Ogusuku IEY, Lameu C, Mayer G, Ulrich H. Aptamers: novelty tools for cancer biology. Oncotarget 2018;9:26934-53. [PMID: 29928493 DOI: 10.18632/oncotarget.25260] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Shraim AS, Abdel Majeed BA, Al-binni MA, Hunaiti A. Therapeutic Potential of Aptamer–Protein Interactions. ACS Pharmacol Transl Sci 2022. [DOI: 10.1021/acsptsci.2c00156] [Reference Citation Analysis]
2 Virgilio A, Pecoraro A, Benigno D, Russo A, Russo G, Esposito V, Galeone A. Antiproliferative Effects of the Aptamer d(GGGT)4 and Its Analogues with an Abasic-Site Mimic Loop on Different Cancer Cells. Int J Mol Sci 2022;23:5952. [PMID: 35682635 DOI: 10.3390/ijms23115952] [Reference Citation Analysis]
3 Shelley G, Dai J, Keller JM, Keller ET. Pheno-SELEX: Engineering Anti-Metastatic Aptamers through Targeting the Invasive Phenotype Using Systemic Evolution of Ligands by Exponential Enrichment. Bioengineering (Basel) 2021;8:212. [PMID: 34940365 DOI: 10.3390/bioengineering8120212] [Reference Citation Analysis]
4 Earnest KG, McConnell EM, Hassan EM, Wunderlich M, Hosseinpour B, Bono BS, Chee MJ, Mulloy JC, Willmore WG, DeRosa MC, Merino EJ. Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX. Sci Rep 2021;11:19174. [PMID: 34580387 DOI: 10.1038/s41598-021-98676-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Khan H, Makwana V, Santos SND, Bonacossa de Almeida CE, Santos-Oliveira R, Missailidis S. Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy. Pharmaceutics 2021;13:1239. [PMID: 34452200 DOI: 10.3390/pharmaceutics13081239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Krüger A, de Jesus Santos AP, de Sá V, Ulrich H, Wrenger C. Aptamer Applications in Emerging Viral Diseases. Pharmaceuticals (Basel) 2021;14:622. [PMID: 34203242 DOI: 10.3390/ph14070622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
7 Carrión-Marchante R, Frezza V, Salgado-Figueroa A, Pérez-Morgado MI, Martín ME, González VM. DNA Aptamers against Vaccinia-Related Kinase (VRK) 1 Block Proliferation in MCF7 Breast Cancer Cells. Pharmaceuticals (Basel) 2021;14:473. [PMID: 34067799 DOI: 10.3390/ph14050473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kharkar PS. Cancer Stem Cell (CSC) Inhibitors in Oncology-A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives. J Med Chem 2020;63:15279-307. [PMID: 33325699 DOI: 10.1021/acs.jmedchem.0c01336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Marshall ML, Wagstaff KM. Internalized Functional DNA Aptamers as Alternative Cancer Therapies. Front Pharmacol 2020;11:1115. [PMID: 32848740 DOI: 10.3389/fphar.2020.01115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Czechowska K, Lannigan J, Wang L, Arcidiacono J, Ashhurst TM, Barnard RM, Bauer S, Bispo C, Bonilla DL, Brinkman RR, Cabanski M, Chang HD, Chakrabarti L, Chojnowski G, Cotleur B, Degheidy H, Dela Cruz GV, Eck S, Elliott J, Errington R, Filby A, Gagnon D, Gardner R, Green C, Gregory M, Groves CJ, Hall C, Hammes F, Hedrick M, Hoffman R, Icha J, Ivaska J, Jenner DC, Jones D, Kerckhof FM, Kukat C, Lanham D, Leavesley S, Lee M, Lin-Gibson S, Litwin V, Liu Y, Molloy J, Moore JS, Müller S, Nedbal J, Niesner R, Nitta N, Ohlsson-Wilhelm B, Paul NE, Perfetto S, Portat Z, Props R, Radtke S, Rayanki R, Rieger A, Rogers S, Rubbens P, Salomon R, Schiemann M, Sharpe J, Sonder SU, Stewart JJ, Sun Y, Ulrich H, Van Isterdael G, Vitaliti A, van Vreden C, Weber M, Zimmermann J, Vacca G, Wallace P, Tárnok A. Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops. Cytometry A 2019;95:598-644. [PMID: 31207046 DOI: 10.1002/cyto.a.23777] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
11 Sola M, Menon AP, Moreno B, Meraviglia-Crivelli D, Soldevilla MM, Cartón-García F, Pastor F. Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge? Mol Ther Nucleic Acids 2020;21:192-204. [PMID: 32585627 DOI: 10.1016/j.omtn.2020.05.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
12 Bing T, Wang J, Shen L, Liu X, Shangguan D. Prion Protein Targeted by a Prostate Cancer Cell Binding Aptamer, a Potential Tumor Marker? ACS Appl Bio Mater 2020;3:2658-65. [PMID: 35025400 DOI: 10.1021/acsabm.0c00024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Kimoto M, Hirao I. New Research Area, Xenobiology, by Integrating Chemistry and Biology. J Synth Org Chem Jpn 2020;78:465-475. [DOI: 10.5059/yukigoseikyokaishi.78.465] [Reference Citation Analysis]
14 Haßel SK, Mayer G. Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided? Mol Diagn Ther 2019;23:301-9. [PMID: 31037641 DOI: 10.1007/s40291-019-00400-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
15 Kimoto M, Shermane Lim YW, Hirao I. Molecular affinity rulers: systematic evaluation of DNA aptamers for their applicabilities in ELISA. Nucleic Acids Res 2019;47:8362-74. [PMID: 31392985 DOI: 10.1093/nar/gkz688] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
16 Guo Y, Pan X, Zhang W, Hu Z, Wong KW, He Z, Li HW. Label-free probes using DNA-templated silver nanoclusters as versatile reporters. Biosens Bioelectron 2020;150:111926. [PMID: 31929081 DOI: 10.1016/j.bios.2019.111926] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
17 Bing T, Zhang N, Shangguan D. Cell-SELEX, an Effective Way to the Discovery of Biomarkers and Unexpected Molecular Events. Adv Biosyst 2019;3:e1900193. [PMID: 32648677 DOI: 10.1002/adbi.201900193] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
18 Drabik A, Ner-Kluza J, Hartman K, Mayer G, Silberring J. Changes in Protein Glycosylation as a Result of Aptamer Interactions with Cancer Cells. Proteomics Clin Appl 2020;14:e1800186. [PMID: 31550741 DOI: 10.1002/prca.201800186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Kudłak B, Wieczerzak M. Aptamer based tools for environmental and therapeutic monitoring: A review of developments, applications, future perspectives. Critical Reviews in Environmental Science and Technology 2020;50:816-67. [DOI: 10.1080/10643389.2019.1634457] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
20 Citartan M, Kaur H, Presela R, Tang TH. Aptamers as the chaperones (Aptachaperones) of drugs-from siRNAs to DNA nanorobots. Int J Pharm 2019;567:118483. [PMID: 31260780 DOI: 10.1016/j.ijpharm.2019.118483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Pleiko K, Saulite L, Parfejevs V, Miculis K, Vjaters E, Riekstina U. Differential binding cell-SELEX method to identify cell-specific aptamers using high-throughput sequencing. Sci Rep 2019;9:8142. [PMID: 31148584 DOI: 10.1038/s41598-019-44654-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
22 Ali MH, Elsherbiny ME, Emara M. Updates on Aptamer Research. Int J Mol Sci. 2019;20:pii: E2511. [PMID: 31117311 DOI: 10.3390/ijms20102511] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 28.0] [Reference Citation Analysis]
23 Tuna BG, Atalay PB, Kuku G, Acar EE, Kara HK, Yilmaz MD, Ozalp VC. Enhanced antitumor activity of carbendazim on HeLa cervical cancer cells by aptamer mediated controlled release. RSC Adv 2019;9:36005-10. [DOI: 10.1039/c9ra07974b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Kumar V, Sharma A. Recent Updates for Isolation of Aptamers for Various Biothreat Agents Using Different Strategies and Their Role in Detection Applications. Aptamers 2019. [DOI: 10.1007/978-981-13-8836-1_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Pleiko K, Saulite L, Parfejevs V, Miculis K, Vjaters E, Riekstina U. Differential binding cell-SELEX method to identify cell-specific aptamers using high-throughput sequencing.. [DOI: 10.1101/466722] [Reference Citation Analysis]
26 Molefe PF, Masamba P, Oyinloye BE, Mbatha LS, Meyer M, Kappo AP. Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases. Pharmaceuticals (Basel) 2018;11:E93. [PMID: 30274155 DOI: 10.3390/ph11040093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Ruiz Ciancio D, Vargas MR, Thiel WH, Bruno MA, Giangrande PH, Mestre MB. Aptamers as Diagnostic Tools in Cancer. Pharmaceuticals (Basel) 2018;11:E86. [PMID: 30208607 DOI: 10.3390/ph11030086] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]